Business Wire
BusinessJPMorgan Chase shares fall even as broader markets rise, ending near $357The Apex TimesBusinessModerna and Merck lift big-biopharma sentiment as Treasury yields ease; S&P 500 and Nasdaq edge higherThe Apex TimesBusinessBank of America turns bullish on Medtronic ahead of earnings, citing a second catalyst buildingThe Apex TimesBusinessTesla’s “Model Y L” heads to the U.S., but investors are asking whether it can restart growthThe Apex TimesBusinessEli Lilly and Novo Nordisk face a new test in the shift from injectable to oral GLP-1 drugs, Yahoo Finance asksThe Apex TimesBusinessModerna stock surges after report of success in melanoma vaccine trialThe Apex TimesBusinessModerna-linked cancer vaccine catalyst lifts shares as BioNTech rally fades in traders’ viewThe Apex TimesBusinessModerna’s Intismeran posts melanoma recurrence win, strengthening the turnaround case for mRNA oncologyThe Apex TimesBusinessBroadcom shares fall after Marvell deal highlights intensifying competition for custom AI chipsThe Apex TimesBusinessGeneral Motors lifts full-year outlook, citing strong first-half results and truck strengthThe Apex TimesBusinessModerna and Merck surge as investors react to “potentially historic” news on personalized mRNA cancer vaccinesThe Apex TimesBusinessBroadcom shares slide more than 20% from June highs as analysts debate how much AI optimism is priced inThe Apex TimesBusinessJPMorgan Chase shares fall even as broader markets rise, ending near $357The Apex TimesBusinessModerna and Merck lift big-biopharma sentiment as Treasury yields ease; S&P 500 and Nasdaq edge higherThe Apex TimesBusinessBank of America turns bullish on Medtronic ahead of earnings, citing a second catalyst buildingThe Apex TimesBusinessTesla’s “Model Y L” heads to the U.S., but investors are asking whether it can restart growthThe Apex TimesBusinessEli Lilly and Novo Nordisk face a new test in the shift from injectable to oral GLP-1 drugs, Yahoo Finance asksThe Apex TimesBusinessModerna stock surges after report of success in melanoma vaccine trialThe Apex TimesBusinessModerna-linked cancer vaccine catalyst lifts shares as BioNTech rally fades in traders’ viewThe Apex TimesBusinessModerna’s Intismeran posts melanoma recurrence win, strengthening the turnaround case for mRNA oncologyThe Apex TimesBusinessBroadcom shares fall after Marvell deal highlights intensifying competition for custom AI chipsThe Apex TimesBusinessGeneral Motors lifts full-year outlook, citing strong first-half results and truck strengthThe Apex TimesBusinessModerna and Merck surge as investors react to “potentially historic” news on personalized mRNA cancer vaccinesThe Apex TimesBusinessBroadcom shares slide more than 20% from June highs as analysts debate how much AI optimism is priced inThe Apex TimesBusinessJPMorgan Chase shares fall even as broader markets rise, ending near $357The Apex TimesBusinessModerna and Merck lift big-biopharma sentiment as Treasury yields ease; S&P 500 and Nasdaq edge higherThe Apex TimesBusinessBank of America turns bullish on Medtronic ahead of earnings, citing a second catalyst buildingThe Apex TimesBusinessTesla’s “Model Y L” heads to the U.S., but investors are asking whether it can restart growthThe Apex TimesBusinessEli Lilly and Novo Nordisk face a new test in the shift from injectable to oral GLP-1 drugs, Yahoo Finance asksThe Apex TimesBusinessModerna stock surges after report of success in melanoma vaccine trialThe Apex TimesBusinessModerna-linked cancer vaccine catalyst lifts shares as BioNTech rally fades in traders’ viewThe Apex TimesBusinessModerna’s Intismeran posts melanoma recurrence win, strengthening the turnaround case for mRNA oncologyThe Apex TimesBusinessBroadcom shares fall after Marvell deal highlights intensifying competition for custom AI chipsThe Apex TimesBusinessGeneral Motors lifts full-year outlook, citing strong first-half results and truck strengthThe Apex TimesBusinessModerna and Merck surge as investors react to “potentially historic” news on personalized mRNA cancer vaccinesThe Apex TimesBusinessBroadcom shares slide more than 20% from June highs as analysts debate how much AI optimism is priced inThe Apex TimesBusinessJPMorgan Chase shares fall even as broader markets rise, ending near $357The Apex TimesBusinessModerna and Merck lift big-biopharma sentiment as Treasury yields ease; S&P 500 and Nasdaq edge higherThe Apex TimesBusinessBank of America turns bullish on Medtronic ahead of earnings, citing a second catalyst buildingThe Apex TimesBusinessTesla’s “Model Y L” heads to the U.S., but investors are asking whether it can restart growthThe Apex TimesBusinessEli Lilly and Novo Nordisk face a new test in the shift from injectable to oral GLP-1 drugs, Yahoo Finance asksThe Apex TimesBusinessModerna stock surges after report of success in melanoma vaccine trialThe Apex TimesBusinessModerna-linked cancer vaccine catalyst lifts shares as BioNTech rally fades in traders’ viewThe Apex TimesBusinessModerna’s Intismeran posts melanoma recurrence win, strengthening the turnaround case for mRNA oncologyThe Apex TimesBusinessBroadcom shares fall after Marvell deal highlights intensifying competition for custom AI chipsThe Apex TimesBusinessGeneral Motors lifts full-year outlook, citing strong first-half results and truck strengthThe Apex TimesBusinessModerna and Merck surge as investors react to “potentially historic” news on personalized mRNA cancer vaccinesThe Apex TimesBusinessBroadcom shares slide more than 20% from June highs as analysts debate how much AI optimism is priced inThe Apex Times
Back to front
Nvidia is reportedly in talks to take a stake in AI data-labeling firm Mercor at a $20 billion valuation
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 5:26 PM EDT

Nvidia is reportedly in talks to take a stake in AI data-labeling firm Mercor at a $20 billion valuation

The chipmaker’s potential investment would come amid a funding round that, according to a report, could lift Mercor’s valuation sharply to $20 billion.

2 min readEditor-approved Apex article

Nvidia is reportedly exploring an investment in Mercor, an AI data-labeling company, as part of a funding round that could value the startup at $20 billion, according to a report cited by Yahoo Finance.

The report says Nvidia has been in talks regarding the potential stake, framing the possible deal as part of the broader ecosystem buildout around artificial intelligence systems that rely on large volumes of labeled or annotated data.

AI data-labeling firms play a specific role in AI training pipelines. Labeled datasets are used to help models learn to recognize patterns, such as identifying objects in images, classifying text, or extracting information from documents. Companies that can produce high-quality labeled data at scale often become upstream inputs for many AI projects.

The valuation reference in the report matters because it indicates how investors and strategic players are viewing supply of AI training data. If the funding round does lift Mercor to a $20 billion valuation, it would place the company in the highest tier of AI infrastructure-related startups, alongside a smaller group of firms focused on chips, data platforms, and model tooling.

For Nvidia, a stake in a data-labeling provider would align with a reality that has emerged across the AI industry: access to compute is necessary but not sufficient. Training and improving machine-learning models also depends on data preparation, curation, and annotation, tasks that are often expensive and operationally complex.

Nvidia has long positioned its technology stack to be used across AI workflows, from training and inference to developer platforms. While the report does not specify how Nvidia would influence Mercor’s operations, strategic investments in AI enablement companies are commonly aimed at tightening the link between hardware capabilities and the software and data processes that put that hardware to work.

The report does not provide deal terms, such as how much Nvidia would invest, the size of the stake, whether it would be structured as equity or another instrument, or whether Nvidia is the lead participant in the round. It also does not disclose whether discussions are at an early exploratory stage, whether other investors are involved, or what conditions could affect the valuation or timing.

Neither Nvidia nor Mercor, in the cited posting, offered an official confirmation of the talks or additional details about the contemplated transaction. That means investors watching the story will likely need to wait for confirmation from company statements, regulatory filings, or funding-round disclosures before drawing conclusions.

Why It Matters

  • If Nvidia participates, it would reflect continued interest in AI infrastructure beyond chips, including the data supply chain used to train models.
  • A $20 billion valuation for a data-labeling provider would underscore how valuable investors view data readiness and quality at scale.
  • The lack of deal specifics indicates uncertainty around timing and whether negotiations would translate into a completed transaction.

Sources

Key Facts

  • Nvidia is reportedly exploring a stake in AI data-labeling firm Mercor.
  • The reported discussions are tied to a funding round that could value Mercor at $20 billion.
  • The report, as cited by Yahoo Finance, frames the possible investment as part of Nvidia’s broader AI ecosystem involvement.
  • The cited reporting does not disclose deal size, stake percentage, or investment structure.

Technology Related